Improving Drug Safety in Pediatric and Young Adult Patients with Hemato-Oncological Diseases: A Prospective Study of Active Pharmacovigilance
Authors:
- Anna ParzianelloAPAnna Parzianello
- Giulia FornasierGFGiulia Fornasier
- Valentina KirenVKValentina Kiren
- Federico PigatoFPFederico Pigato
- Sabrina OrzettiSabrina Orzetti
- Giulia ZamagniGZGiulia Zamagni
- Anna ArboAAAnna Arbo
- Paolo BaldoPaolo Baldo
- Paola RossiPRPaola Rossi
- Marco RabusinMRMarco Rabusin
- Maurizio MascarinMMMaurizio Mascarin
- Marta Paulina TrojniakMTMarta Paulina Trojniak
Open Access
- 12 January 2024
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (1) , 106
Abstract
The acquisition of relevant pediatric clinical safety data is essential to ensure tolerable drug therapies. Comparing the real number of Adverse Drug Reaction (ADR) reports in clinical practice with the literature, the idea of ADR underreporting emerges. An active pharmacovigilance observational prospective study was conducted to assess the safety of oncology pharmacological prescriptions in patients aged 0–24 years at Institute for Maternal and Child Health IRCCS Burlo Garofolo in Trieste and IRCCS CRO National Cancer Institute in Aviano (Italy) between January 2021 and October 2023. Prescriptions and ADRs were evaluated by a multidisciplinary team. A total of 1218 prescriptions for 38 patients were analyzed, and 190 ADRs of grade 3–5 were collected. As compared to historical data, we registered a significant increase (p < 0.001) in the number of ADRs. The risk of ADR was 3.4 times higher in the case of off-label prescriptions compared to on-label ones (OR 3.4; [1.47; 7.89]; p-value = 0.004). The risks of error and near-miss were reported for 6.3% and 18.2% of total prescriptions, respectively. Of the total of 133 interactions, 47 (35.3%) resulted in ADRs. This study shows the importance of pro-active pharmacovigilance to efficiently highlight ADRs, and the fundamental role of multidisciplinary teams (oncologist, pharmacist, pharmacologist, pediatrician, nurse) in improving patients’ safety during therapy.Keywords
Funding Information
- Ministero della Salute (RC 15\22)
This publication has 18 references indexed in Scilit:
- A systematic review of clinical pharmacist interventions in paediatric hospital patientsEuropean Journal of Pediatrics, 2018
- Chemotherapy medication errorsThe Lancet Oncology, 2018
- Off-label and unlicensed drug use in children populationTherapies, 2018
- The impact of pharmacist telephone calls after discharge on satisfaction of oncology patients: A randomized controlled studyJournal of Oncology Pharmacy Practice, 2017
- Drug-drug interactions in pediatric oncology patientsPediatric Blood & Cancer, 2017
- Medication Reconciliation in Oncological Patients: A Randomized Clinical TrialJournal of Managed Care & Specialty Pharmacy, 2016
- How to promote adverse drug reaction reports using information systems – a systematic review and meta-analysisBMC Medical Informatics and Decision Making, 2016
- Chemotherapy prescribing errors: an observational study on the role of information technology and computerized physician order entry systemsBMC Health Services Research, 2013
- Evaluation of clinical interventions made by pharmacists in chemotherapy preparationRadiology and Oncology, 2010
- Interventions of Hospital Pharmacists in Improving Drug Therapy in ChildrenDrug Safety, 2006